Publication | Open Access
The Molecular Story of COVID-19; NAD<sup>+</sup><sup> </sup>Depletion Addresses All Questions in this Infection
33
Citations
28
References
2020
Year
Acute Lung InjuryInflammatory Lung DiseaseLung InflammationViral PathogenesisImmunologyCell DeathViral Structural ProteinOxidative StressCovid-19InflammationViral PersistenceInfection ControlHost-pathogen InteractionsNew Coronaviridae MemberMolecular SignalingCovid-19 PandemicVirologyReactive Oxygen SpecieCell BiologyClinical MicrobiologyMolecular MedicineNcov 19PathogenesisEndothelial DysfunctionMicrobiologyMedicineMolecular Story
The emerging new Coronaviridae member, nCoV 19, outbreak announced a pandemic by WHO with an increased morbidity and mortality rate worldwide. nCoV 19 known as the third highly pathogen coronavirus in the human population after the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), the nCoV 19. The renin-angiotensin (RAS) signaling pathway, oxidative stress and cell death, cytokines storm and endothelial dysfunction are four major pathways involved in the pathogenesis of nCoV 19. Acute respiratory distress syndrome (ARDS) generally develops with a massive oxidative/nitrosative stress following virus entry and RAS activation. The DNA damage subsequent to oxidative burst activates poly-ADP ribose polymerase-1 (PARP-1), viral macrodomain (NSP3) poly (ADP-ribose) glycohydrolase (PARG) and transient receptor potential channel, melastatin 2 (TRPM2) in a sequential manner ultimately leading to apoptosis and necrosis due to NAD and ATP depletion. Regarding the molecular mechanisms involved in nCoV 19 pathogenesis, angiotensin II receptor blockers and/or PARP, PARG and TRPM2 blockers could be engaged as therapeutic candidates for inhibition of RAS and quenching oxidative stress, respectively. In this review, the molecular aspects of nCoV 19 pathogenesis would be studied precisely and possible therapeutic targets would be proposed. It is recommended to evaluate the proposed drugs and supplements via registered clinical trials along with conventional guideline-based multi-drug regimen.
| Year | Citations | |
|---|---|---|
Page 1
Page 1